10/566856

Cofc

Docket No.: 17243/004001
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of:
Heinz W. Gschwend et al.

Patent No.: 7,514,436

Issued: April 7, 2009

For: PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

REQUEST FOR CERTIFICATE OF CORRECTION
PURSUANT TO 37 CFR 1.322

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

In the Claims:

In Claim 1, column 40, line 22, "R_{7a}" should be --$\mathbf{R^{7a}}$--.

In Claim 15, column 43, line 17, "C_7-C_{12}" should be --$\mathbf{C_2}$-$\mathbf{C_{12}}$--.

In Claim 21, column 44, line 14, "{-[6-(Methyl-phenethyl-amino)pyridazin-3-yl]" should be --**{4-[6-(Methyl-phenethyl-amino)-pyridazin-3-yl]**--.

In Claim 27, column 45, line 13, the word "hydroxyl" should be --**hydroxy**--.

In Claim 27, column 45, line 17, the word "hydroxyl" should be --**hydroxy**--.

In Claim 27, column 45, line 17, "C_1-C_6trihaloalkyl and" should be **--C_1-C_6trihaloalkyl,--**.

In Claim 28, column 46, line 9, the word "amoun" should be **--amount--**.

The errors were not in the application as filed by applicant; accordingly no fee is required.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment. Also enclosed, as evidence of the errors, is a copy of the claims as issued, and a copy of the Claims as allowed. Patentee respectfully solicits the granting of the requested Certificate of Correction.

Applicant believes no fee is due with this request. However, if a fee is due, please charge our Deposit Account No. 50-0591, under Order No. 17243/004001.

Dated: May 8, 2009

Respectfully submitted,

By _____

T. Chyau Liang, Ph.D.
Registration No.: 48,885
OSHA · LIANG LLP
909 Fannin Street, Suite 3500
Houston, Texas 77010
(713) 228-8600
(713) 228-8778 (Fax)

Fatty acids are analyzed as follows: The reaction mixture is saponified with 10% KOH to obtain free fatty acids which are further methylated using BF_3 in methanol. The fatty acid methyl esters are analyzed by high performance liquid chromatography (HPLC) using a Hewlett Packard 1090, Series II chromatograph equipped with a diode array detector set at 205 nm, a radioisotope detector (Model 171, Beckman, CA) with a solid scintillation cartridge (97% efficiency for ^{14}C-detection) and a reverse-phase ODS (C-18) Beckman column (250 mm×4.6 mm i.d.; 5 μm particle size) attached to a pre-column with a μBondapak C-18 (Beckman) insert. Fatty acid methyl esters are separated isocratically with acetonitrile/water (95:5 v:v) at a flow rate of 1 mL/min and are identified by comparison with authentic standards. Alternatively, fatty acid methyl esters may be analyzed by capillary column gas-chromatography (GC) or Thin Layer Chromatography (TLC).

Those skilled in the art are aware of a variety of modifications to this assay that can be useful for measuring inhibition of stearoyl-CoA desaturase activity in microsomes by test compounds.

Representative compounds of the invention showed activity as inhibitors of SCD when tested in this assay. The activity was defined in terms of % SCD enzyme activity remaining at the desired concentration of the test compound.

All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entirety.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

What is claimed is:

1. A compound of formula (I):

(I)



wherein:

x and y are each independently 1;

W is —O—, —C(O)O—, —N(R^1)—, —S(O)$_t$— (where t is 0, 1 or 2), —N(R^1)S(O)$_2$—, —OC(O)— or —C(O)—;

V is —C(O)—, —C(S)—, —C(O)N(R^1)—, —C(O)O—, —S(O)$_2$—, or —S(O)$_2$N(R^1)—;

each R^1 is independently selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_2-C_{12}hydroxyalkyl, C_4-C_{12}cycloalkylalkyl and C_7-C_{19}aralkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl, provided that when W is —O—, R^2 is not C_1-C_{12}alkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is —C(O)— or —C(O)O—, R^3 is not C_1-C_{12}alkyl;

or R^3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^4 and R^5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or —N(R^{13})$_2$;

R^6, R^{6a}, R^7, R_{7a}, R^8, R^{8a}, R^9 and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl; and

each R^{13} is independently selected from hydrogen or C_1-C_6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

2. A compound of formula (Ia):

(Ia)



wherein:

x and y are each independently 1;

W is —O—, —C(O)O—, —N(R^1)—, —S(O)$_t$— (where t is 0, 1 or 2), —N(R^1)S(O)$_2$—, —OC(O)— or —C(O)—;

V is —C(O)—, —C(S)—, —C(O)N(R^1)—, —C(O)O—, —S(O)$_2$—, or —S(O)$_2$N(R^1)—;

each R^1 is independently selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_2-C_{12}hydroxyalkyl, C_4-C_{12}cycloalkylalkyl and C_7-C_{19}aralkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl, provided that, when W is —C(O)—, R^2 can not be C_1-C_6alkyl substituted by —S(O)$_t$$R^{14}$ where R^{14} is hydrogen, C_1-C_6alkyl, C_7-C_{12}aralkyl, pyrazinyl, pyridinonyl, pyrrolidionyl or imidazolyl, provided that when W is —O—, R^2 is not C_1-C_{12}alkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is —C(O)— or —C(O)O—, R^3 is not C_1-C_{12}alkyl;

or R^3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^4 and R^5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $—N(R^{13})_2$;

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl; and

each R^{13} is independently selected from hydrogen or C_1-C_6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

3. The compound of claim **2** wherein:

x and y are each 1;

W is —O—;

V is —C(O)— or —C(S)—;

R^2 is selected from the group consisting of C_1-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is —C(O)—, R^3 is not C_1-C_{12}alkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

4. The compound of claim **3** wherein:

V is —C(O)—;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

5. The compound of claim **4** wherein:

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

6. The compound of claim **5**, namely, [4-(6-Phenethyloxy-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone.

7. The compound of claim **3** wherein:

V is —C(O)—;

R^2 is C_1-C_{12}alkyl or C_2-C_{12}alkenyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

8. The compound of claim **3** wherein:

V is —C(O)—;

R^2 is C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

9. The compound of claim **8** wherein:

R^2 is C_4-C_{12}cycloalkylalkyl; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

10. The compound of claim **9**, namely, {4-[6-(2-Cyclopropyl-ethoxy)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

11. The compound of claim **2** wherein:

x and y are each 1;

W is $—S(O)_t—$ (where t is 0, 1 or 2);

V is —C(O)— or —C(S)—;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is —C(O)—, R^3 is not C_1-C_{12}alkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

12. The compound of claim **11** wherein:

V is —C(O)—;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

13. The compound of claim 12 wherein:
R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy; and
R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

14. The compound of claim 13 selected from the group consisting of the following:
[4-(6-Phenethylsulfanyl-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone;
{4-[6-(2-Phenyl-ethanesulfinyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone; and
{4-[6-(2-Phenyl-ethanesulfonyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

15. The compound of claim 11 wherein:
V is —C(O)—;
R^2 is C_1-C_{12}alkyl or C_7-C_{12}alkenyl;
R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and
each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

16. The compound of claim 15 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

17. The compound of claim 16, namely, {4-[6-(3-Methyl-butylsulfanyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

18. The compound of claim 2 wherein:
x and y are each 1;
W is $—N(R^1)—$;
V is —C(O)— or —C(S)—;
R^1 is hydrogen or C_1-C_6alkyl;
R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;
R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is —C(O)—, R^3 is not C_1-C_{12}alkyl;
R^4 and R^5 are each hydrogen; and
R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

19. The compound of claim 18 wherein:
V is —C(O)—;
R^1 is hydrogen or C_1-C_6alkyl;
R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;
R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and
each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

20. The compound of claim 19 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

21. The compound of claim 20 selected from the group consisting of the following:
[4-(6-Phenethylamino-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; and
{-[6-(Methyl-phenethyl-amino)pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

22. The compound of claim 18 wherein:
V is —C(O)—;
R^1 is hydrogen or C_1-C_6alkyl;
R^2 is C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;
R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and
each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

23. The compound of claim 2 wherein:
x and y are each 1;
W is $—N(R^1)S(O)_2—$;
V is —C(O)— or —C(S)—;
R^1 is hydrogen or C_1-C_6alkyl;
R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;
R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is —C(O)—, R^3 is not C_1-C_{12}alkyl;
R^4 and R^5 are each hydrogen; and
R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

24. The compound of claim 23 wherein:
V is —C(O)—;
R^1 is hydrogen or C_1-C_6alkyl;
R^2 is C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;
R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and
each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

25. The compound of claim 24 wherein:

R^2 is C_1-C_{12}alkyl; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

26. The compound of claim 25, namely, Propane-1-sulfonic acid {6-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-pyridazin-3-yl}-amide.

27. The compound of claim 23 wherein:

V is —C(O)—;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxyl, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxyl, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $—N(R^{12})_2$, $—OC(O)R^{12}$, $—C(O)OR^{12}$, $—S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

28. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amoun of a compound of claim 2.

29. An in vivo method for inhibiting stearoyl-CoA desaturase, compising contacting a source of stearoyl-CoA desaturase with a compound of claim 1.

30. An in vivo method for inhibiting stearoyl-CoA desaturase, comprising contacting a source of stearoyl-CoA desaturase with a compound of claim 2.

* * * * *

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

x and y are each independently 1;

W is -O-, -C(O)O-, -N(R^1)-, -S($O)_t$- (where t is 0, 1 or 2), -N(R^1)S($O)_2$-, -OC(O)- or -C(O)-;

V is -C(O)-, -C(S)-, -C(O)N(R^1)-, -C(O)O-, -S($O)_2$-, or -S($O)_2$N(R^1)- ~~or -C(R^{11})H-~~;

each R^1 is independently selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_2-C_{12}hydroxyalkyl, C_4-C_{12}cycloalkylalkyl and C_7-C_{19}aralkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl, provided that when W is –O-, R^2 is not C_1-C_{12}alkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is –C(O)- or –C(O)O-, R^3 is not C_1-C_{12}alkyl;

or R^3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^4 and R^5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or $-N(R^{13})_2$;

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl;

~~R^{11} is C_1-C_3alkyl~~; and

each R^{13} is independently selected from hydrogen or C_1-C_6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

2. – 9. (Canceled)

10. (Currently Amended) A compound of formula (Ia):



(Ia)

wherein:

x and y are each independently 1;

W is -O-, -C(O)O-, $-N(R^1)$-, $-S(O)_t$- (where t is 0, 1 or 2), $-N(R^1)S(O)_2$-, -OC(O)- or -C(O)-;

V is -C(O)-, -C(S)-, $-C(O)N(R^1)$-, -C(O)O-, $-S(O)_2$-, or $-S(O)_2N(R^1)$- ~~or $-C(R^{11})H$-~~;

each R^1 is independently selected from the group consisting of hydrogen, C_1-C_{12}alkyl, C_2-C_{12}hydroxyalkyl, C_4-C_{12}cycloalkylalkyl and C_7-C_{19}aralkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl, provided that, when W is -C(O)-, R^2 can not be C_1-C_6alkyl substituted by $-S(O)_tR^{14}$ where R^{14} is hydrogen, C_1-C_6alkyl, C_7-C_{12}aralkyl, pyrazinyl, pyridinonyl, pyrrolidionyl or imidazolyl, provided that when W is –O-, R^2 is not C_1-C_{12}alkyl;

or R^2 is a multi-ring structure having 2 to 4 rings wherein the rings are

independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is –C(O)- or –C(O)O-, R^3 is not C_1-C_{12}alkyl;

or R^3 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;

R^4 and R^5 are each independently selected from hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, cyano, nitro or -$N(R^{13})_2$;

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each independently selected from hydrogen or C_1-C_3alkyl;

~~R^{11} is C_1-C_3alkyl;~~ and

each R^{13} is independently selected from hydrogen or C_1-C_6alkyl;

a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof or a prodrug thereof.

11. (Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is -O-;

V is -C(O)- or -C(S)-;

R^2 is selected from the group consisting of C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{19}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is –C(O)-, R^3 is not C_1-C_{12}alkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

12. (original) The compound of Claim 11 wherein:

V is -C(O)-;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

13. (original) The compound of Claim 12 wherein:

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

14. (original) The compound of Claim 13, namely, [4-(6-Phenethyloxy-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone.

15. (original) The compound of Claim 11 wherein:

V is -C(O)-;

R^2 is C_1-C_{12}alkyl or C_2-C_{12}alkenyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

16. (original) The compound of Claim 11 wherein:

V is -C(O)-;

R^2 is C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $-N(R^{12})_2$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

17. (original) The compound of Claim 16 wherein:

R^2 is C_4-C_{12}cycloalkylalkyl; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

18. (original) The compound of Claim 17, namely, {4-[6-(2-Cyclopropyl-ethoxy)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

19. (Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is $-S(O)_t-$ (where t is 0, 1 or 2);

V is -C(O)- or -C(S)-;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is –C(O)-, R^3 is not C_1-C_{12}alkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

20. (original) The compound of Claim 19 wherein:

V is -C(O)-;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $-N(R^{12})_2$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

21. (original) The compound of Claim 20 wherein:

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

22. (original) The compound of Claim 21 selected from the group consisting of the following:

[4-(6-Phenethylsulfanyl-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone;

{4-[6-(2-Phenyl-ethanesulfinyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone; and

{4-[6-(2-Phenyl-ethanesulfonyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

23. (original) The compound of Claim 19 wherein:

V is -C(O)-;

R^2 is C_1-C_{12}alkyl or C_2-C_{12}alkenyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $-N(R^{12})_2$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl,

aryl or aralkyl.

24. (original) The compound of Claim 23 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

25. (original) The compound of Claim 24, namely, {4-[6-(3-Methyl-butylsulfanyl)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

26. (Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is -N(R^1)-;

V is -C(O)- or -C(S)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is –C(O)-, R^3 is not C_1-C_{12}alkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

27. (original) The compound of Claim 26 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy,

C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

28. (original) The compound of Claim 27 wherein R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

29. (original) The compound of Claim 28 selected from the group consisting of the following:

[4-(6-Phenethylamino-pyridazin-3-yl)-piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; and

{4-[6-(Methyl-phenethyl-amino)-pyridazin-3-yl]-piperazin-1-yl}-(2-trifluoromethyl-phenyl)-methanone.

30. (original) The compound of Claim 26 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

31. (Previously Presented) The compound of Claim 10 wherein:

x and y are each 1;

W is -$N(R^1)S(O)_2$-;

V is -C(O)- or -C(S)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl,

C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl, and C_3-C_{12}heteroarylalkyl;

R^3 is selected from the group consisting of C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_2-C_{12}hydroxyalkyl, C_2-C_{12}hydroxyalkenyl, C_2-C_{12}alkoxyalkyl, C_3-C_{12}cycloalkyl, C_4-C_{12}cycloalkylalkyl, aryl, C_7-C_{12}aralkyl, C_3-C_{12}heterocyclyl, C_3-C_{12}heterocyclylalkyl, C_1-C_{12}heteroaryl and C_3-C_{12}heteroarylalkyl, provided that when V is –C(O)-, R^3 is not C_1-C_{12}alkyl;

R^4 and R^5 are each hydrogen; and

R^6, R^{6a}, R^7, R^{7a}, R^8, R^{8a}, R^9 and R^{9a} are each hydrogen.

32. (original) The compound of Claim 31 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_1-C_{12}alkyl, C_2-C_{12}alkenyl, C_3-C_{12}cycloalkyl or C_4-C_{12}cycloalkylalkyl;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, -$N(R^{12})_2$, -$OC(O)R^{12}$, -$C(O)OR^{12}$, -$S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

33. (original) The compound of Claim 32 wherein:

R^2 is C_1-C_{12}alkyl; and

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy.

34. (original) The compound of Claim 33, namely, Propane-1-sulfonic acid {6-[4-(2-trifluoromethyl-benzoyl)-piperazin-1-yl]-pyridazin-3-yl}-amide.

35. (original) The compound of Claim 31 wherein:

V is -C(O)-;

R^1 is hydrogen or C_1-C_6alkyl;

R^2 is C_7-C_{12}aralkyl optionally substituted by one or more substituents selected

from halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl and C_1-C_6trihaloalkoxy;

R^3 is phenyl optionally substituted by one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxy, C_1-C_6alkyl, C_1-C_6trihaloalkyl, C_1-C_6trihaloalkoxy, C_1-C_6alkylsulfonyl, $-N(R^{12})_2$, $-OC(O)R^{12}$, $-C(O)OR^{12}$, $-S(O)_2N(R^{12})_2$, cycloalkyl, heterocyclyl, heteroaryl and heteroarylcycloalkyl; and

each R^{12} is independently selected from hydrogen, C_1-C_6alkyl, C_3-C_6cycloalkyl, aryl or aralkyl.

36. (Canceled).

37. (original) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of Claim 10.

38. (New) A method for inhibiting stearoyl-CoA desaturase, comprising contacting a source of stearoyl-CoA desaturase with a compound of claim 1.

39. (New) A method for inhibiting stearoyl-CoA desaturase, comprising contacting a source of stearoyl-CoA desaturase with a compound of claim 10.

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,514,436

APPLICATION NO. : 10/566,856

ISSUE DATE : April 7, 2009

INVENTOR(S) : Heinz W. Gschwend et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

In Claim 1, column 40, line 22, "R_{7a}" should be --$\mathbf{R^{7a}}$--.

In Claim 15, column 43, line 17, "C_7-C_{12}" should be --$\mathbf{C_2}$-$\mathbf{C_{12}}$--.

In Claim 21, column 44, line 14, "{-[6-(Methyl-phenethyl-amino)pyridazin-3-yl]" should be --**{4-[6-(Methyl-phenethyl-amino)-pyridazin-3-yl]**--.

In Claim 27, column 45, line 13, the word "hydroxyl" should be --**hydroxy**--.

In Claim 27, column 45, line 17, the word "hydroxyl" should be --**hydroxy**--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
T. Chyau Liang, Ph.D.
OSHA · LIANG LLP
909 Fannin Street, Suite 3500
Houston, Texas 77010

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO.	:	7,514,436
APPLICATION NO.	:	10/566,856
ISSUE DATE	:	April 7, 2009
INVENTOR(S)	:	Heinz W. Gschwend et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In Claim 27, column 45, line 17, "C_1-C_6trihaloalkyl and" should be --**C_1-C_6trihaloalkyl,**--.

In Claim 28, column 46, line 9, the word "amoun" should be --**amount**--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):
T. Chyau Liang, Ph.D.
OSHA · LIANG LLP
909 Fannin Street, Suite 3500
Houston, Texas 77010

PTO/SB/92 (04-09)
Approved for use through 05/31/2009. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Application No. (if known): 10/566,856 Attorney Docket No.: 17243/004001

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Attention: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on May 8, 2009
Date



Signature

Minh S. Thach
Typed or printed name of person signing Certificate

48,885
Registration Number, if applicable

(713) 228-8600
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Request for Certificate of Correction (No Fee) with attachments (16 pages)
Certificate of Correction (2 pages)
Return Receipt Post Card